Bipolar I Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Bipolar I Disorder Market Outlook
Thelansis’s “Bipolar I Disorder Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Bipolar I Disorder treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Bipolar I Disorder Overview
Bipolar I
disorder is a persistent mental health condition characterized by alternating
phases of heightened mood, known as mania, and low mood, known as depression.
Mania is described as a distinct period of excessively elevated, expansive, or
irritable mood, accompanied by increased activity or energy, lasting at least a
week and occurring most days, often requiring hospitalization if shorter. This
disorder affects approximately 1 in 100 adults, posing a significant public
health concern. It typically manifests with a mix of manic and depressive
symptoms, leading to severe disruptions in mood lasting weeks or months,
impacting various aspects of daily life and functioning. While the
monoaminergic neurotransmitter systems—such as serotonin, norepinephrine, and
dopamine—have been central to theories and research on mood disorder origins,
no single neurotransmitter system dysfunction has been conclusively identified
in bipolar disorder despite evidence suggesting their involvement.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment